Daily news and information for physicians in a range of specialties and practice settings.
The FDA Bone, Reproductive, and Urologic Drugs Advisory Committee voted in favor of approving romosozumab for the treatment of postmenopausal women with osteoporosis at high risk for fracture.  
Coronary artery disease remains the top killer of Americans—these tools may help identify people who are still at risk.
University of Pennsylvania investigators conducted an interim analysis of a year-long study on intraocular injections of a mutation-specific gene therapy when one patient showed dramatic early improvements.
A new review shows transgender women face higher HIV rates than transgender men, but also finds a relative lack of data about transmen.
Meta-analysis of other randomized controlled trials have shown that vitamin D supplementation reduces the risk of acute respiratory infections and exacerbations of asthma.
Ocrelizumab demonstrated superiority to or comparability with 14 other disease-modifying therapies currently approved by the European Medicines Agency.  
The FDA has responded to the Janssen Pharmaceutical company's sNDA with a request for more data.
This is the first generic approval of the tablet form of vigabatrin, which is indicated for treating focal seizures in patients with epilepsy.
The FDA has approved a scalpel-free method for the treatment of patients with Parkinson disease who experience tremors and are medication-resistant. 
Currently in phase 1 testing, ACX-362E is being developed as a narrow spectrum antibiotic for the treatment of Clostridium difficile infection.
Copyright© MD Magazine 2006-2018 Intellisphere, LLC. All Rights Reserved.